Pleiotropic effects: Should statins be considered an essential component in the treatment of dyslipidemia?

Current Atherosclerosis Reports

Volumn 10, Issue 1, 2008, Pages 45-52

  Mays, Maureen E ^a   Dujovne, Carlos A ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ATORVASTATIN; BETA CAROTENE; BILE ACID SEQUESTRANT; COLESTIPOL; FENOFIBRATE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL PRESSURE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MONOTHERAPY; MYALGIA; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PLEIOTROPY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MYOCARDIAL INFARCTION; PPAR GAMMA; RISK FACTORS; THROMBOSIS;

EID: 40749104579     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0008-0     Document Type: Review

References (50)

1. The Expert Panel: Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988, 148:36-69.
2. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89:1329-445.
3. Dujovne CA: The clinical-therapeutic implications of the Scandinavian Simvastatin Survival Study. Am J Cardiol 1997, 79:1387-1388.
4. Downs JR, Learfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998, 279:1615-1622.
5. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
6. Third Report National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143.
7. Ray KK, Cannon CP: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005, 46:1425-1433.
8. Shepherd J, Blauw GJ, Murphy MB, et al, PROSPER study group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002, 360:1623-1630.
9. Sever PS, Dahlof B, Poulter NR, et al., ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
10. Nissen SE, Nicholls SJ, Sipahi I, et al., for the ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
11. Auer J, Berent R, Weber T, et al.: Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 2002, 9:1831-1850.
12. Kamai T, Metsumoto N, Koitabashi Y, et al.: Pleiotropic effects of 3-hydroxy-3-mehtylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem 2005, 3:195-201.
13. Liao JK: Effects of statins on HMG-CoA reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005, 96(suppl):24F-33F.
14. Zucker ML, Trowbridge C, Krehbeil P, et al.: Platelet function in hypercholesterolemics before end after hypolipidemic drug therapy. Haemostasis 1986, 16:57-64.
15. Davignon J, Leiter LA: Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005, 1:29-40.
16. Ray KK, Cannon CP, Ganz P: Beyond lipid lowering what have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006, 98(Suppl):18P-25P.
17. Wierzbicki AS, Lumb PJ, Semra YK, et al.: Effect of atorvastatin on plasma fibrinogen. Lancet 1998, 351:569-570.
18. Golledge J, Greenhalhg RM, Davies AH: The symptomatic carotid plaque. Circulation 2000, 31:774-781.
19. Bocan TM: Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Invest Drugs 2002, 3:1312-1317.
20. Solomon DH, Karlson EW, Rimm EB, et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
21. del Rincon ID, Williams K, Stern MP, et al.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
22. Ray KK, Cannon CP: Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol 2005, 96(Suppl):54F-60F.
23. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
24. Sander D, Winbeck K, Klingelhofer J, et al.: Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002, 106:2428-2433.
25. Ridker PM: C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007, 49:2129-2138.
26. Kinlay S: Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. J Am Coll Cardiol 2007, 49:2003-2009.
27. Tsimikas S: Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006, 98(Suppl):9P-17P.
28. Mason RP: Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006, 98(Suppl):34P-41P.
29. Libby P, Sasiela W: Plaque stabilization: can we turn theory into evidence? Am J Cardiol 2006, 98(Suppl):26P-33P.
30. Brown G, Albers J, Fisher L, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
31. Mehta JL: Pleiotropic effects of statins: how important are they in the prevention of vascular disease? Endothelium 2003, 10:3-4.
32. Arora R, Liebo M, Maldonado F: Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther 2006, 11:105-112.
33. Olson KL, Brand DW, McGinnis B, et al.: A determination of the reasons why patients discontinue statin therapy (abstract 58). Paper presented at the American College of Clinical Pharmacy Annual Meeting. San Francisco, California; October 23-26, 2005.
34. Lesaffre E, Kocmanova D, Lemos PA, et al.: A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003, 25:2431-2447.
35. Spencer FA, Fonarow GC, Frederick PD, et al.: Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 2004, 164:2162-2168.
36. McGowan MP; TNT Study Group: There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004, 110:2280-2282.
37. Puccetti L, Pasqui AL, Pastorelli, et al.: Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost 2003, 90:476-482.
38. Chu CS, Lee KT, Lee MY, et al.: Effects of atorvastatin and atorvastatin withdrawal on soluble DC40L and adipocytokines in patients with hypercholeserolaemia. Acta Cardiol 2006, 61:263-269.
39. Cubeddu LX, Seamon MJ: Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 2006, 26:1288-1296.
40. Taneva E, Borucki K, Wiens L, et al.: Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006, 97:1002-1006.
41. Vogel RA: Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol 2001, 88:31E-34E.
42. Chapman MJ, Assmann G, Fruchart JC, et al.: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid? A position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
43. Lakshman MR, Gottipati CS, Narasimhan SJ, et al.: Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 2006, 55:1201-1206.
44. Lupattelli G, Marchesi S, Lombardini R, et al.: Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia. Metabolism 2003, 52:1191-1195.
45. Okopie AB, Haberka M, Madej A, et al.: Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep 2006, 58:729-735.
46. Olsson AG, Schwartz GG, Szarek M, et al.: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005, 26:890-896.
47. Mendez M, LaPointe MC: PPAR inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003, 42:844-850.
48. Nesto RW, Plutzky J: The vascular effects of TZDs: stabilizing plaque in an unstable environment. Online CME presentation by the University of Wisconsin School of Medicine and Public Health. Released April 26, 2006. Available at http://www.medscape.com/viewprogram/5173. Accessed on September 13, 2007.
49. Dujovne CA: Side effects of statins: hepatitis vs transaminitis, myositis vs CPKitis. Am J Cardiol 2002, 89:1411-1413.
50. Shepherd J: Who should receive a statin these days? J Intern Med 2006, 260:305-319.